---
title: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
date: '2023-12-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38078508/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231212170745&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: MRD-directed ibrutinib-venetoclax improved progression-free
  survival as compared with FCR, and results for overall survival also favored ibrutinib-venetoclax.
  (Funded by Cancer Research UK and others; FLAIR ISRCTN Registry number, ISRCTN01844152;
  EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: MRD-directed ibrutinib-venetoclax improved progression-free survival as compared with FCR, and results for overall survival also favored ibrutinib-venetoclax. (Funded by Cancer Research UK and others; FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, ...